Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1CNS 1

Conditions

Head and Neck Neoplasms 2604Squamous Cell Carcinoma of Head and Neck 1880Thyroid Neoplasms 705Nasopharyngeal Carcinoma 627Carcinoma, Non-Small-Cell Lung 478Mouth Neoplasms 424Breast Neoplasms 383Neoplasms 381Oropharyngeal Neoplasms 359Melanoma 339Lung Neoplasms 319Colorectal Neoplasms 307Carcinoma, Squamous Cell 283Neoplasm Metastasis 255Ovarian Neoplasms 254Laryngeal Neoplasms 253Salivary Gland Neoplasms 236Uterine Cervical Neoplasms 234Stomach Neoplasms 223Esophageal Neoplasms 222Nasopharyngeal Neoplasms 221Pancreatic Neoplasms 213Prostatic Neoplasms 203Carcinoma, Renal Cell 201Thyroid Nodule 179Thyroid Cancer, Papillary 178Urinary Bladder Neoplasms 163Sarcoma 160Recurrence 143Hypopharyngeal Neoplasms 143

Interventions

spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disorders of Sex Development × Head & Neck × Clear all
NCT02605967 2022-02-10

Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Novartis

Phase 2 Completed
122 enrolled 28 charts
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Recurrence, Disorders of Sex Development

Data powered by HemOnc (CC BY 4.0) Colophon âš¡